Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IM96 CAR-T cells in advanced digestive system neoplasms
NCT05287165Phase 1Unknown
- Sponsor
- Immunochina Pharmaceuticals
- Start
- Mar 2022
- Primary completion
- Apr 2024
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of IM96 in digestive system neoplasms, colorectal cancer (CRC), pancreatic cancer (PC) and 3 more, sponsored by Immunochina Pharmaceuticals. Primary endpoint: Incidence of Treatment Related adverse events at 28 days. Status: unknown.
02
Drugs
IM96
03
Conditions
digestive system neoplasmscolorectal cancer (CRC)pancreatic cancer (PC)gastric cancer (GC)esophageal cancer
Beyond the preview
Go deeper on NCT05287165.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05287165.